Eun-Jeong Kim1, Xiaoyan Yin2, João D Fontes2, Jared W Magnani3, Steve A Lubitz4, David D McManus5, Sudha Seshadri6, Ramachandran S Vasan7, Patrick T Ellinor4, Martin G Larson8, Emelia J Benjamin9, Michiel Rienstra10. 1. Department of Medicine, Section of General Internal Medicine, Massachusetts General Hospital, Boston, MA. 2. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA. 3. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA; Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA. 4. Cardiovascular Research Center and Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, MA; Program in Medical and Population Genetics, The Broad Institute of Harvard and MIT, Cambridge, MA. 5. Departments of Medicine and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA. 6. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA; Departments of Neurology, Boston University School of Medicine, Boston, MA. 7. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA; Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA; Section of Preventive Medicine, Department of Medicine, Boston University School of Medicine, MA. 8. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA; Department of Mathematics and Statistics, Boston University, MA; Department of Biostatistics, Boston University School of Public Health, MA. 9. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA; Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA; Section of Preventive Medicine, Department of Medicine, Boston University School of Medicine, MA; Department of Epidemiology, Boston University School of Public Health, Boston, MA. 10. Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: m.rienstra@umcg.nl.
Abstract
BACKGROUND: The epidemiology of atrial fibrillation (AF) without comorbidities, known as 'lone AF', is uncertain. Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a matched sample without AF. METHODS: We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and triggers) among the entire AF sample in Framingham Heart Study (FHS). We compared AF without comorbidities with typical AF, and age-, sex- and cohort-matched individuals without AF, using Cox proportional hazards analysis in relation to combined cardiovascular events (stroke, heart failure, myocardial infarction), and mortality. RESULTS: Of 10,311 FHS participants, 1,961 were diagnosed with incident AF, among which 173 individuals had AF without comorbidities (47% women, mean age 71±12 years). AF without comorbidities had a prevalence of 1.7% of the entire cohort, and an annual incidence of 0.5 per 1000 person-years. During a median follow-up of 9.7 years after initial AF, 137 individuals with AF without comorbidities (79.2%) died and 141 individuals developed cardiovascular events (81.5%). AF without comorbidities had significantly lower mortality (HR 0.67, 95%CI 0.55-0.81, P < .001) and total cardiovascular events (HR 0.66, 95% CI 0.55-0.80, P < .001) compared with typical AF. However, mortality (HR1.43, 95% CI 1.18-1.75, P < .001) and risk of total cardiovascular events (HR 1.73, 95% CI 1.39-2.16, P < .001) were higher than age-, sex-, and cohort-matched individuals without AF. CONCLUSIONS: The risk of cardiovascular outcomes and mortality among individuals with AF without comorbidities is lower than typical AF, but is significantly elevated compared with matched individuals without AF.
BACKGROUND: The epidemiology of atrial fibrillation (AF) without comorbidities, known as 'lone AF', is uncertain. Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a matched sample without AF. METHODS: We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and triggers) among the entire AF sample in Framingham Heart Study (FHS). We compared AF without comorbidities with typical AF, and age-, sex- and cohort-matched individuals without AF, using Cox proportional hazards analysis in relation to combined cardiovascular events (stroke, heart failure, myocardial infarction), and mortality. RESULTS: Of 10,311 FHS participants, 1,961 were diagnosed with incident AF, among which 173 individuals had AF without comorbidities (47% women, mean age 71±12 years). AF without comorbidities had a prevalence of 1.7% of the entire cohort, and an annual incidence of 0.5 per 1000 person-years. During a median follow-up of 9.7 years after initial AF, 137 individuals with AF without comorbidities (79.2%) died and 141 individuals developed cardiovascular events (81.5%). AF without comorbidities had significantly lower mortality (HR 0.67, 95%CI 0.55-0.81, P < .001) and total cardiovascular events (HR 0.66, 95% CI 0.55-0.80, P < .001) compared with typical AF. However, mortality (HR1.43, 95% CI 1.18-1.75, P < .001) and risk of total cardiovascular events (HR 1.73, 95% CI 1.39-2.16, P < .001) were higher than age-, sex-, and cohort-matched individuals without AF. CONCLUSIONS: The risk of cardiovascular outcomes and mortality among individuals with AF without comorbidities is lower than typical AF, but is significantly elevated compared with matched individuals without AF.
Authors: Tatjana S Potpara; Goran R Stankovic; Branko D Beleslin; Marija M Polovina; Jelena M Marinkovic; Miodrag C Ostojic; Gregory Y H Lip Journal: Chest Date: 2011-05-26 Impact factor: 9.410
Authors: L Mont; A Sambola; J Brugada; M Vacca; J Marrugat; R Elosua; C Paré; M Azqueta; G Sanz Journal: Eur Heart J Date: 2002-03 Impact factor: 29.983
Authors: S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye Journal: N Engl J Med Date: 1987-09-10 Impact factor: 91.245
Authors: Michael M McNeil; Susan K Duderstadt; Jennifer F Sabatier; Gina G Ma; Jonathan Duffy Journal: Hum Vaccin Immunother Date: 2019-01-08 Impact factor: 3.452
Authors: Stephanie R Reading; Mary Helen Black; Daniel E Singer; Alan S Go; Margaret C Fang; Natalia Udaltsova; Teresa N Harrison; Rong X Wei; In-Lu Amy Liu; Kristi Reynolds Journal: BMC Cardiovasc Disord Date: 2019-02-11 Impact factor: 2.298
Authors: Jakub Gumprecht; Magdalena Domek; Marco Proietti; Yan-Guang Li; Nidal Asaad; Wafa Rashed; Alawi Alsheikh-Ali; Mohammad Zubaid; Gregory Y H Lip Journal: J Clin Med Date: 2020-04-29 Impact factor: 4.241
Authors: Matthew J Singleton; Muhammad Imtiaz-Ahmad; Hooman Kamel; Wesley T O'Neal; Suzanne E Judd; Virginia J Howard; George Howard; Elsayed Z Soliman; Prashant D Bhave Journal: J Am Heart Assoc Date: 2020-06-04 Impact factor: 5.501
Authors: Nathan C Denham; Charles M Pearman; Jessica L Caldwell; George W P Madders; David A Eisner; Andrew W Trafford; Katharine M Dibb Journal: Front Physiol Date: 2018-10-04 Impact factor: 4.566
Authors: Carlos Arturo Areán Martínez; Fernando Lanas; Ghazi Radaideh; Suleiman M Kharabsheh; Marc Lambelet; Marco Antonio Lavagnino Viaud; Naser Samih Ziadeh; Alexander G G Turpie Journal: Egypt Heart J Date: 2018-09-24